A longitudinal, qualitative and quantitative exploration of daily life and need for rehabilitation among patients with high-grade gliomas and their caregivers

K Piil,1,2 M Jarden,2 J Jakobsen,3 K Bang Christensen,4 M Juhler1,5

ABSTRACT

Introduction: High-grade gliomas (HGGs) are the most malignant type of brain tumours. The 5-year survival is 10% and a significant part of the ongoing research aims to increase survival through surgical and oncological treatments. Accordingly, there is an increasing need for investigating the HGG trajectory in order to recommend specific guidelines for rehabilitative and supportive interventions.

Method and analysis: This study protocol (phase I) describes a longitudinal, qualitative, explorative and descriptive interview study of the life situation and need for rehabilitation among patients and their caregivers and a quantitative evaluation of health-related quality of life. Qualitative and quantitative data are collected in parallel, analysed separately and then merged. The finding of this study will, together with the existing literature, form the background for phase II, which is a feasibility study with a pre-experimental one-group design testing a rehabilitative and supportive intervention programme. The aim of this paper was to describe the design of an upcoming study. Interviews with 30 patients and 30 caregivers will provide information about how the life situation is experienced during the first year after being diagnosed with HGG. Quantitative measurements of quality of life, well-being and physical activity will provide additional information. More precisely, both qualitative and quantitative data will support the planning of the programme regarding the type of intervention(s), with or without supervision, the appropriate time along the trajectory, frequency, localisation, endpoint measurements and eligible patients and/or caregivers.

Ethics and dissemination: According to the Research Ethics Committee, approval is not needed for phase I as it is a non-intervention part of the study. Ethical approval of phase II will be sought at the time where the content of the intervention programme has been developed. Dissemination will occur through presentation and findings will be published in peer-reviewed journals.

ARTICLE SUMMARY

Article focus

This protocol article describes a mixed-method longitudinal study of the life situation among patients newly diagnosed with high-grade glioma (HGG) and their caregivers. The supportive, rehabilitative and palliative needs and preferences during the first year after diagnosis will be explored in order to develop a rehabilitation programme that targets these special needs.

Key messages

- The literature that addresses the supportive, rehabilitative and palliative needs still remains limited and reflects a gap in the existing knowledge regarding the breadth of needs across the disease and treatment trajectory for patients with HGG and their caregivers.
- Patients and their caregivers might have different needs for support, rehabilitation and palliation at various stages of the disease and treatment trajectory.
- Few intervention studies have been conducted in patients with HGG, leaving the present evidence for specific guidelines for the supportive, rehabilitative and palliative interventions poor.

Strengths and limitations of this study

- A key strength of this study is its mixed-methods longitudinal design including the perspectives of both the patient and their caregiver. A potential limitation is the uncertainty of recruitment immediately after surgery (1–2 days postoperative), as well as the risk of dropout due to non-adherence, inability to comply or death in patients with HGG and their caregivers during longitudinal research.

BACKGROUND

Primary brain cancer accounts for 2% of all cancer cases.1 High-grade glioma (HGG) is the most malignant type of brain tumour...
(WHO classification grade III/IV) occurring most frequently in people aged 45–70 years. Median survival time is 12–15 months and the 5-year survival is 10%. A significant part of the ongoing research aims to increase survival through surgical and oncological treatments, and this has resulted in a gradual improvement in prognosis over the past three decades. Accordingly, there is an increasing need for investigation of the HGG disease and treatment trajectory in order to recommend specific guidelines for the supportive, rehabilitative and palliative interventions.

The current standard combined modality treatment for HGG consists of surgery followed by daily outpatient radiation therapy and 6 weeks of concomitant chemotherapy (temozolomide). After a pause of 23 days, a new cycle of chemotherapy is repeated. A total of six cycles of adjuvant temozolomide is administered to each patient. A curative treatment does not exist, but radiation and chemotherapy have a life-prolonging effect. Treatment response is evaluated by brain imaging and typically carried out prior to the third and sixth treatment cycles (see figure 1). In case of tumour progression, suitable patients can be offered reoperation or treatment with an angiogenesis inhibitor (Bevacizumab) in combination with chemotherapy (Irinotecan).

Patients with HGG differ from other patients with cancer in that these tumours cause damage to brain function and the nervous system. Being diagnosed with HGG has been shown to result in a significant symptom burden related to both the disease and the treatment. All types of cerebral symptoms can occur including global cerebral symptoms (fatigue, nausea, headaches, confusion), focal symptoms (hemiparesis, seizures and speech difficulties), neurocognitive deficits (aphasia, impaired attention, concentration difficulties, reduced short-term memory, personality changes) and emotional symptoms such as depression and anxiety. Several of these symptoms have been shown to influence both survival and quality of life (QOL). Impairment of the physical condition and fatigue are prominent symptoms which reduce QOL during the postoperative period. The degree of cognitive impairment and the grade of malignancy exert a negative influence on the patient’s perception of QOL. One study found that the patient’s level of independence was an indicator of survival. In line with that, exercise behaviour has been found to be a strong independent predictor of survival.

Glucocorticoids are commonly administered in palliative treatment to decrease tumour or radiation-associated oedema. However, steroids cause significant toxicity with prolonged use, and frequently result in systemic and cerebral side effects, for example, excitement, insomnia, hyperglycaemia, gastric disturbances, osteoporosis and loss of muscle strength, which may also influence QOL.

Previous studies show that social relationships between the patient and their relatives change as the relative becomes the nearest caregiver. The caregiver is a key resource for the patient, often taking necessary responsibility for the patient throughout the course of treatments. However, caregivers are overwhelmed by the new situation often requiring support. Several studies show that the QOL of the caregiver is negatively affected by the patient’s disease. Both the patient and the caregiver experience agony, and have spiritual and existential considerations. Most caregivers find that their relation to the workforce is adversely affected and they experience stress. Very little is known about how the patients and their caregivers experience the disease and treatment across the trajectory. It is unclear which needs are present at different stages, how these needs are best addressed and by whom. Few intervention studies have been conducted and as a consequence, no guidelines regarding the supportive, rehabilitative and palliative interventions exist, and the evidence for the development of such specific guidelines is poor.

Figure 1 Treatment trajectory and study evaluation (phase I).
rehabilitative and palliative needs remains limited and diffuse, and reflects a gap in the existing knowledge regarding the breadth of needs across the disease and treatment trajectory for patients with HGG and their caregivers. Further, combining qualitative interviews and quantitative patient-reported outcomes to study QOL, emotional well-being and level of physical activity has not yet been carried out in patients with HGG and their caregivers applying a longitudinal design. The reason for converging the two forms of data is to bring greater insight into the aims of this study than would be obtained by either type of data separately.

Aim
The study comprises two consecutive phases. The primary aim of phase I was to explore the life situation, needs and experiences across a 1-year disease and treatment continuum in patients newly diagnosed with HGG and their caregivers. Furthermore, the preferences for the supportive, rehabilitative and palliative interventions during and after surgical and medical treatment for HGG will be investigated. Specifically, the aims were:

- To gain insight into the life situation of patients and their caregivers during the first year after diagnosis.
- To systematically assess the patient’s need for support, rehabilitation and palliation throughout the course of the disease.
- To describe how symptoms are experienced and managed.
- To elucidate the resources of the caregivers and any independent needs related to the patient’s disease.
- To gain an understanding of what a comprehensive survivorship programme should comprise.
- To develop a targeted rehabilitation programme for patients with HGG and their caregivers.

The aim of phase II was to study the feasibility of a rehabilitation programme designed from the existing literature and from the experiences of the patients and their caregivers obtained in the present study (phase I). The pilot study (phase II) will investigate the feasibility, adherence, safety and preliminary benefits of recruiting patients with HGG and their caregivers for participation in the supportive, rehabilitative and palliative interventions. The precise study design of phase II is dependent on the results of phase I and will therefore not be described in further detail in this article.

METHODS

Study participants and sampling
Patients will be recruited by a criterion sampling strategy. The criteria includes a diagnosis of HGG (WHO classification grade III/IV) in persons >18 years of age who are capable of speaking and understanding Danish and who have a Karnofsky performance score (KPS) >60 at baseline. The rationale for KPS >60 is to assure recruitment of the best informants. Since the present study requires active and independent participation during the interview sessions and in filling out the questionnaires, KPS >60 is considered a necessary requirement for adequate participation. Whether patients with cognitive deficits will be able to participate in the study will depend on the judgements of clinical specialists such as the neurosurgeon, the neuropsychologist and the nurses. Caregivers are eligible if they are named by the patient as the most involved caregiver, and will provide written informed consent. To ensure adequate sample size and optimal recruitment, the following has been taken into consideration: first, in order to ascertain data saturation at each test point during the entire course of the study (1 year), the sample size at baseline takes into account an expected drop-out rate of 50% at the final test (12 months). The number of newly diagnosed patients with HGG (WHO classification grades III and IV) at Rigshospitalet is approximately 90 during a 6-month period. Based on an estimated reduction of 50% in the number of patients at the final test (1 year from baseline), the necessary sample size is estimated to be 30 patients and 30 caregivers. The expected drop-out rate of 50% is based on the poor prognosis of a median survival time at 12–15 months. Furthermore, it is unknown if participants will experience research participation over 1 year to be too burdensome. It is a risk that a proportion of patients and/or caregivers will dropout or be non-respondents at any of the five test time point. Still, it was decided not to increase the sample size by recruiting new patients/caregivers during the study period due to dropouts, as the study would then lose its longitudinal design for each participant. Second, recruiting patients with or without caregivers and caregivers with or without patients will be accepted.

Recruitment
The investigator (neuro-oncology nurse specialist) will consecutively identify eligible patients and ask for participation 1–2 days after the operation. The rationale for this time frame is that patients are often discharged 1–2 days after surgery, and therefore, the process of screening, recruiting and informing potential participants in person is a priority of the investigator for the main purpose of fulfilling eligibility and selection requirements, and assessing performance status. Further, since data generation (interviews and questionnaires) will not be face-to-face, but provided by telephone, the initial meeting with the patient enables personal contact. Patients and caregivers might be in a state of initial shock and distress at this time, which calls for careful consideration when recruiting this group of patients and their caregivers to research, for example, it is important to limit participants’ response burden. Patient motivation has been found to be of considerable importance in the successful collection of QOL data. Patients and caregivers will be informed and asked to sign the consent form before the patient is discharged from the hospital.

Design
This is a convergent parallel design.48 Both qualitative and quantitative methods will be applied in this study. The approach for data collection in this mixed methods study is a concurrent approach,48 52 where qualitative and quantitative data are collected in parallel, analysed separately and then merged.48 The quantitative data seek to demonstrate that the variables are systematically related and the qualitative data seek to provide insight into how they are related.52 A qualitative approach allows the participants to express and describe experiences and thoughts regarding their new life situation in their own words. The quantitative patient-reported psychometric questionnaires will provide additional information to the findings obtained in the interviews. The dominant status relies on the qualitative data as the serial interviews are emphasised as the best suited method to address the primary aim of this study.49 The quantitative data are viewed as a useful supplementary data source. The qualitative and quantitative data will be integrated during the interpretation and the findings will draw inferences using both approaches. The feasibility of using questionnaires in this longitudinal design will be explored.

Theoretical framework
Owing to the complexity of the disease, its treatment and an uncertain life situation, the theoretical framework for this study is the biopsychosocial model.27 The biopsychosocial perspective suggests that the biological, psychological and social factors all play a significant role for human functions related to the disease. The interview guide is constructed in accordance with this perspective.

Qualitative data
The semistructured interviews53 will elucidate the subjective experience of having been diagnosed with and treated for HGG and the experience of being a caregiver. In addition to the biopsychosocial perspective, professional knowledge of the disease and course of treatment are incorporated in the construction of the semistructured interview guide. The semistructured interview guide has been developed in accordance with the disease and treatment conditions, for example, surgery (test 1), oncological treatment (test 2), treatment response scans and oncological treatment (tests 3 and 4) and life after standard treatment (test 5). The interview topics for patients appear in table 1 and for caregivers in table 2.

After the initial face-to-face encounter during recruitment, five separate interviews with the patient and their caregiver will take place over the course of a year. The interviews will be conducted by telephone. The decision to choose telephone interviews as the most appropriate method for data collection at multiple time points is based on evidence in the literature. Telephone interviewing is not only an inexpensive and time-saving method,54 55 but also it has been evaluated as a valid and useful method in qualitative research.56 57 Moreover, telephone contact may allow participants to feel relaxed during the interview sessions. Some participants may regard a face-to-face interview as a burden, owing to the need to invite the investigator as a guest in their home.56 Also, it has been found that participants are more likely to report sensitive behaviours when the interviewer is not physically present.47 Telephone interviewing is a flexible method for the patient, the caregiver and the interviewer. It is a convenient way of arranging individual appointments: the interview can be divided into two parts if the participants need a break, and a telephone interview can be scheduled outside working hours. Finally, the interviewer avoids long transportation time and costs. Although telephone interviews have been noted to be impersonal and not ‘the gold standard’ for collecting data related to sensitive topics,59 the method has many advantages, without existing proof of inferiority.58 The participants (patient and the caregiver) are encouraged to carry out the interviews alone so that the conversation is not influenced by the presence of others. However, it will be accepted if the patient needs help/assistance from their caregiver during the interview.

Quantitative data
Information about the socioeconomic conditions, disease and treatment variables will be obtained by the investigator at baseline. The disease, treatment and clinical variables will be collected throughout the duration of the study, including KPS, which will be obtained by a medical chart review at each test point. Patients will receive three questionnaires by mail at the time of each interview with written instructions to fill out and return in the enclosed stamped addressed envelope. The validated patient-reported questionnaires are (1) Functional Assessment of Cancer Therapy-Brain (FACT-Br), which is an instrument measuring the general QOL and specific symptoms or problems associated with brain cancer. It contains five subscales: physical well-being, social/family well-being, emotional well-being, functional well-being and disease-specific concerns.60 (2) The Hospital Anxiety and Depression Scale (HADS) is a short instrument that measures the levels of anxiety and depression, using items that avoid reliance on aspects such as fatigue and insomnia that are common somatic symptoms of illness. It contains two subscales, one measuring anxiety and the other measuring depression.61 (3) Physical activity levels will be measured using a single item adapted from Saltin,62 where patients rate their physical activity level using four response options ‘Almost completely inactive’: reading, watching TV etc; ‘Some physical activity during less than three hours per week’; riding a bicycle or walking; ‘Regular physical activity for at least 3 h/week’; and ‘Hard physical exercise for more than 4 h/week’. Additionally, at baseline, patients will also be asked to report retrospectively what their level of activity
Table 1  Interview topics for patients

<table>
<thead>
<tr>
<th>Research questions</th>
<th>Examples of interview questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>What happened and how did the patient experience the time between the first symptoms and the operation?</td>
<td>How did you find out that you were sick? Describe what happened and how did you experience the episode? What has happened since the last interview? How have you been since the last interview?</td>
</tr>
<tr>
<td>Does the patient experience any symptoms/side effects, and what are the consequences and how are they managed?</td>
<td>Do you have any complaints/symptoms/side effects? Does it have any effect on the way that you manage your life? Is there anything that has helped you to overcome the symptoms/side effects? Have you noticed difficulties in remembering, reading or in attention? Have you noticed whether you have changed your way of behaving? How do you cope/manage with this? How is your mood?</td>
</tr>
<tr>
<td>How are everyday life, work, network and support experienced?</td>
<td>Can you describe a typical day? Has it changed from earlier? What do you usually do in your spare time? Do you/can you enjoy yourself now? How would you describe your network? Do you have children? How are they affected? What attitudes/reactions have you experienced to your disease? How is your working situation? Have you changed anything in the way you live your life (eg, diet, exercise, everyday activities, social contacts)</td>
</tr>
<tr>
<td>Are there any changes in lifestyle?</td>
<td>Is there anything you find difficult to do?</td>
</tr>
<tr>
<td>How does the patient experience the communication and information with the health professionals?</td>
<td>What have the health professionals told you about your disease? What do you think about that information? Do you lack any information? Have you looked for information—of what kind and where? How do you think about the way the health professionals address you?</td>
</tr>
<tr>
<td>Does the patient experience challenges during everyday activities?</td>
<td>What would be the best thing that anyone could do for you these days? Do you need any advice on how to handle your situation/condition/symptoms or everyday activities? Are you getting the support you need from the family/hospital/general practitioner?</td>
</tr>
<tr>
<td>What are the needs for rehabilitation?</td>
<td>Can you imagine being physically active now, and how do you prefer to be active? How many hours a week are you physically active now? Can you imagine accepting psychological support to handle your situation? Can you imagine getting help to exercise your memory and attention? What do you do to help yourself? Would you like to participate in physical exercise, cognitive training and/or psychosocial support? (think about preferences, type, location, frequency, duration, supervised or not supervised)</td>
</tr>
<tr>
<td>Is the patient motivated to meet her/his needs? Any preferences?</td>
<td>Have you considered any alternative treatment to relieve your situation/condition? Please tell me about your considerations</td>
</tr>
<tr>
<td>What are the preferences of the patient in relation to support and rehabilitation?</td>
<td>Are you worried about your financial situation?</td>
</tr>
<tr>
<td>Does the patient seek help from alternative therapy as a supplement to standard treatment?</td>
<td>What needs are the most important for you to meet? Have you done anything to solve an unmet need? Do you have suggestions to how we could improve the situation/condition for future patients? Is there any advice you would give other patients being diagnosed with this type of brain tumour? Is there anything else you would like to tell me/or ask me about?</td>
</tr>
</tbody>
</table>

was at 3 months prior to diagnosis. The total completion time for filling out all questionnaires is approximately 7–15 min.

Ethical issues
This study poses no serious ethical problems. The study is registered at The Research Ethics Committees at the Regional capital (33460). According to the Research Ethics Committee, approval is not needed for phase I as it is the non-intervention part of the study; however, ethical approval will be sought for phase II. It has been registered by the Danish Data Protection Agency (2007-58-0015) and will be carried out in accordance with the Declaration of Helsinki. Written consent will be obtained from each participant, including permission to record the telephone interviews and to use anonymised quotes. Participants will not be identifiable and the authors will disseminate the findings in peer-reviewed publications and at relevant conferences.

Data collection and study evaluation
Participants will be interviewed individually five times over a 12-month period starting at baseline (test 1: time of diagnosis). Test 2 takes place 5–6 weeks postoperatively, which is approximately 2 weeks after initiation of the oncological treatment. Test 3 is at 28 weeks (after first treatment response scan), test 4 is at 40 weeks (after second treatment response scan) and the final test (test...
This interview will be scheduled approximately 2 months postbereavement.

**ANALYSIS**

The semistructured interviews will be recorded and transcribed in full length by either the interviewer or a research assistant. Interview data will be transferred to the NVivo V.9 software program. This program allows transparency in the process from raw data (interview transcripts) to comprehensive understanding, which

<table>
<thead>
<tr>
<th>Table 2 Interview topics for caregivers</th>
<th>Examples of interview questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>How did you experience the period between the first symptoms and the operation?</td>
<td>How did you find out that X was sick? Describe what you observed, what happened and how you did experience that period? How was it to be a caregiver while X was admitted to hospital? What has happened since the last interview?</td>
</tr>
<tr>
<td>Does the caregiver experience that the patient has any symptoms/side effects, what are the consequences and how are they managed?</td>
<td>How would you describe what X experiences these days? Do you observe any symptoms/side effects? Does it have any effect on the way you live your life? Is there anything that has helped you to manage X’s symptoms/side effects? Have you observed any difficulties in remembering, reading or attending for X? Has he/she changed personality/way of behaving? How does that affect you? Have you ever thought that brain cancer differs from other types of cancer? Please tell me about this</td>
</tr>
<tr>
<td>How is everyday life, network and support? What norms and attitudes do the caregivers experience? Are there any changes in behaviour?</td>
<td>Can you describe a typical day? Has that changed from earlier? What do you usually do during your spare time? Do you enjoy yourself now? Are there family friends that have special meaning to you after X got sick? How? Do you have children? How are they affected? How would you describe your network? What attitudes/reactions to the disease, do you meet? How is your working situation right now? Have you changed anything in the way you live your life (eg, diet, every day activities)?</td>
</tr>
<tr>
<td>How does the caregiver experience the communication and information with the health professionals?</td>
<td>What have the health professionals told you about X’s disease? Did you receive the right amount of information? How did you find the written information? Do you lack any information? Have you looked for information, of what kind and where? How do you find the way the health professionals address you? Do you experience practical problems in your life after X became diseased? Have you taken on another role since X became sick? How does it affect you?</td>
</tr>
<tr>
<td>Does the caregiver experience any challenges in the physical environment? What are the needs of rehabilitation? Is the caregiver motivated to meet her/his own needs?</td>
<td>What would be the best thing someone can do for you right now? Do you need any advice on how to handle your situation? Are you getting the support you need from family/hospital/general practitioner? Is this a stressful period for you? Do you experience any symptoms, physical problems?</td>
</tr>
<tr>
<td>What are the preferences of the caregivers in relation to support and rehabilitation?</td>
<td>What do you do to help yourself (physical, social and psychological activities)? Would you like to participate in a support group/information group? Think about preferences, type, location, frequency, duration, supervised or not supervised support</td>
</tr>
<tr>
<td>Does the caregiver seek help from alternative methods as a supplement to standard treatment? Are there financial worries and how important are they? How does the caregiver prioritise her/his own needs?</td>
<td>Have you considered any alternative treatment to relieve your or X’s situation/condition? Are you worried about your financial situation now that X is sick?</td>
</tr>
</tbody>
</table>

5) is at 52 weeks. It is the aim that both tests 3 and 4 should take place approximately 1 week after the results of the response scan are known by the patient and the caregiver. The five test points (figure 1) are selected in order to study the variations in needs along the treatment trajectory. The patients will be asked to complete questionnaires at all five test points. The patient and the caregiver will be interviewed separately within the same week in order to seek perspective on their life situation within the same time frame. A final interview will be conducted with the caregiver in case the patient dies.
The NEuro-ONcological Rehabilitation Protocol | NEON-Rehab

The aim of this paper was to describe the design and methods of an upcoming qualitative and quantitative longitudinal research study. Interviews with 30 patients and 30 caregivers will provide information regarding their experiences during the first year after diagnosis of an HGG. Quantitative measurements of QOL, emotional well-being and physical activity provide additional information. The data will create the basis for a rehabilitation programme regarding the content and timing of such supportive, rehabilitative and palliative interventions.

The overall aim was to develop a tailored and multidimensional rehabilitation programme for patients with HGG and their caregivers. The key to good clinical care is to understand what is important to the patients and their caregivers during various phases of the cancer trajectory. Interventions that target support, information, communication and improve physical and cognitive function in daily life can be important to facilitate a reduced feeling of distress and to increase QOL. This study seeks to support future evidence for guidelines regarding the supportive, rehabilitative and palliative interventions for patients with HGG and their caregivers.

Author affiliations
1Department of Neurosurgery, The University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
2The University Hospitals Center for Health Research (UCSF), Center for Integrated Rehabilitation for patients with Cancer (CIRE), Copenhagen, Denmark
3The University Hospital of Copenhagen, Rigshospitalet, Neuroscience Center, Copenhagen, Denmark
4Department of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
5Department of Clinical Medicine, Section of Neurology, Psychiatry and Sensory Sciences, The University of Copenhagen, Copenhagen, Denmark

Contributors KP, MJA, JKJ, KBC and MJU were involved in the contribution and design of the study, KP participated in the drafting of the article and revising for important intellectual content. All authors have read and approved the final manuscript.

Funding The study is supported by grants from The Center for Integrated Rehabilitation of Cancer patients (CIRE), a centre established and supported by The Danish Cancer Society and The Novo Nordisk Foundation. Furthermore, it is supported by The Neuro Center at Copenhagen University Hospital, Rigshospitalet in Denmark, The Novo Nordisk Foundation, The Capital Regional Research Foundation, Torben and Alice Frimodts Foundation, Vera and Flemming Westerbergs Foundation and Hetland Olsen’s Foundation.

Competing interests None.

Ethics approval Study was registered in 2012 at The Research Ethics Committees at the Regional capital under the number 33460. However, the Research Ethics Committee responded that approval is not needed before the intervention study will be developed. At that time the researcher will seek ethical approval. Study has been approved by the Danish Data Protection Agency (2007-58-0015). The study will be carried out in accordance with the Declaration of Helsinki (WHO, 2000).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


A longitudinal, qualitative and quantitative exploration of daily life and need for rehabilitation among patients with high-grade gliomas and their caregivers

K Pii, M Jarden, J Jakobsen, K Bang Christensen and M Juhler

BMJ Open 2013 3:
doi: 10.1136/bmjopen-2013-003183

Updated information and services can be found at:
http://bmjopen.bmj.com/content/3/7/e003183

These include:

References
This article cites 57 articles, 8 of which you can access for free at:
http://bmjopen.bmj.com/content/3/7/e003183#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Neurology (391)
- Oncology (402)
- Palliative care (72)
- Qualitative research (673)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/